Eli Lilly’s new price target is above the stock’s recent record high. Is this stock a buy?

Here’s our Club Mailbag email [email protected] — so you send your questions directly to Jim Cramer and his team of analysts. We can’t offer personal investing advice. We will only consider more general questions about the investment process or stocks in the portfolio or related industries.

This week’s question: I’m learning so much from the Club about when to buy and sell. One piece of the puzzle that still confuses me is the price target. Using Eli Lilly as an example: Jim posted a new 12-month price target of $600 on Aug. 9 and the stock is around $528 on Aug. 11. A purchase now would result in a nice increase. Of course, getting shares at a lower cost would be more profitable, but I would also not want to give up a potential gain. How does an investor take the price target into consideration? — Thank you, Kathy


Read original article here

Denial of responsibility! Todays Chronic is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – todayschronic.com. The content will be deleted within 24 hours.

Leave a Comment